The Canadian health regulator Health Canada has approved two formulations of Celltrion’s biosimilar to Johnson & Johnson’s Stelara (ustekinumab) following their filing last year.
Marketed under the name Steqeyma (CT-P43), the biosimilar will soon be available to Canadian patients as subcutaneous
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?